Outcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited standalone and consolidated financial results for Q3 and 9M FY26 on February 14, 2026. The company, which recently rebranded from Kapil Cotex Ltd to Skybiotech Healthcare Ltd (effective Nov 7, 2025), is pivoting into healthcare via its subsidiary Skybiotech Lifesciences Pvt Ltd. On a standalone basis, the old business shows zero revenue from operations and a Q3 net loss of Rs 6.41 lakhs. On a consolidated basis, revenue from operations fell sharply to Rs 96.27 lakhs in Q3 FY26 from Rs 252.13 lakhs in Q3 FY25, a roughly 62% year-on-year decline. The consolidated net loss for Q3 widened to Rs 48.47 lakhs (from Rs 39.48 lakhs loss in Q3 FY25), and the 9M FY26 net loss stood at Rs 81.30 lakhs. The auditor (SPD & Associates) issued an unmodified limited review report.
The sharp drop in consolidated revenue and continued losses signal that the transition from the old cotton/textile business to healthcare is still in early stages and the stock remains a loss-making small-cap. Shareholders should watch for revenue traction from the subsidiary and any further capital raises, as the company is currently burning cash with no standalone operations.